Keap1在前列腺癌中的表达和临床意义

目的探讨Kelch样环氧氯丙烷相关蛋白1（Keapl）在前列腺组织中的表达与临床意义。方法2001年1月至2008年10月手术治疗的前列腺癌患者（73例）和良性前列腺增生患者73例，通过免疫组织化学方法检测Keapl蛋白在前列腺癌和良性前列腺增生中的表达，并探讨其表达的临床意义。结果Keap1蛋白在前列腺癌组织中阳性表达率21．9％，显著低于良性前列腺增生组织82．2％（P〈0．05）；Keap1蛋白的的阳性表达率与前列腺癌患者的年龄和T分类无关，与患者的Gleason评分、有无淋巴结转移和远处转移相关（P〈0．05）；Kaplan-Meier生存分析结果显示Keap1蛋白阳性表达的患者5年生存率显著高于于阴性表达的患者（P=0．04）结论Keap1蛋白可能是前列腺癌发生和发展中的重要参与者。

Objective To examine the expression ofKelch-like ECH-associated protein 1 （ Keapl ） in benign prostate hyperplasia and prostate cancer, and explore the relationship between Keap 1 expression and prostate cancer.Methods Specimens from 73 patients with prostate cancer managed in our hospital between January 2001 and October 2008 were included in this study. Immunohistochemical staining was used to detect the expression of Keapl in benign prostate hyperplasia and prostate cancer. All the specimens were confirmed by pathology for benign prostate hyperplasia or prostate cancer. Results The positive expression rate of Keapl in benign prostate hyperplasia and prostate cancer were 82.2% and 21.9%, respectively. The positive expression rate of Keapl in prostate cancer was significantly lower than those in benign prostate hyperplasia （ P〈0.05 ） . The Keapl expression in prostate cancer has nothing to do with the age and T stage （ P〉0.05 ） , but with Gleason score, lymph node and distant metastasis （ P〈0.05 ） . Furthermore, the lower expression of Keapl Keapl was associated with a poorer survival （ P=-0.011 ） .Conclusion Keapl play an important role in the pathology and development of prostate cancer, and could be an important therapeutic target in the treatment of prostate cancer